Antiproliferative and apoptotic effects of pinocembrin in human prostate cancer cells
| Autor: | Rehana Iqbal, Xiaomeng Li, Chaoyue Zhao, Ichiro Tsuji, Faya Martin Millimouno, Azhar Rasul, Takaki Yamamura, Jiang Li, Mahadev Malhi, Chen Zhenyu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
medicine.medical_specialty
Apoptosis Biology urologic and male genital diseases Prostate cancer chemistry.chemical_compound DU145 Internal medicine Pinocembrin LNCaP medicine Viability assay Pharmacology Cell growth lcsh:RM1-950 Cell cycle medicine.disease Endocrinology lcsh:Therapeutics. Pharmacology chemistry Cancer cell Cancer research LNCaP cell LNCaP cells |
| Zdroj: | Bangladesh Journal of Pharmacology, Vol 8, Iss 3 (2013) Bangladesh Journal of Pharmacology, Vol 8, Iss 3, Pp 255-262 (2013) |
| ISSN: | 1991-0088 |
| Popis: | Pinocembrin, (5, 7-dihydroxyflavanone), has been shown to possess anticancer activity against various cancer cells. However, its effect against prostate cancer cells remained enigmatic. In this study, for the first time, we investigated whether pinocembrin could inhibit growth of human prostate cancer cells. MTT assay and flow cytometric analysis were performed to examine the effects of pinocembrin on cell proliferation, cell cycle, and apoptosis. The results revealed that pinocembrin attenuated the cell viability of both androgen-sensitive (LNCaP) as well as androgen-independent (PC3 and DU145) prostate cancer cell lines, with different p53 status. Further characterization showed that pinocembrin markedly induced apoptosis of LNCaP cells and arrested cell cycle at S and G2/M phase and involved in the dissipation of mitochondrial membrane potential before culminating in apoptosis in pinocembrin-treated LNCaP cells. These in vitro results suggested that pinocembrin should be further examined for in vivo activity in human prostate cancer. Article Info |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|